Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
- PMID: 27668059
- PMCID: PMC5013849
Item in Clipboard
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
Am Health Drug Benefits.
2016 Mar.
No abstract available
Similar articles
-
Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.Future Cardiol. 2016 Mar;12(2):115-28. doi: 10.2217/fca.15.78. Epub 2016 Jan 20. Future Cardiol. 2016. PMID: 26785741 Review.
-
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.Lipids Health Dis. 2016 Mar 12;15:55. doi: 10.1186/s12944-016-0227-2. Lipids Health Dis. 2016. PMID: 26968977 Free PMC article.
-
PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.Future Cardiol. 2016 Mar;12(2):149-57. doi: 10.2217/fca.15.88. Epub 2016 Feb 25. Future Cardiol. 2016. PMID: 26911710 Review.
-
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.Drugs Today (Barc). 2016 Mar;52(3):183-92. doi: 10.1358/dot.2016.52.3.2440527. Drugs Today (Barc). 2016. PMID: 27186592 Review.
-
[PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®].Vnitr Lek. 2015 Nov;61(11):946-51. Vnitr Lek. 2015. PMID: 26652782 Review. Czech.
Cited by
-
From target discovery to clinical drug development with human genetics.Nature. 2023 Aug;620(7975):737-745. doi: 10.1038/s41586-023-06388-8. Epub 2023 Aug 23. Nature. 2023. PMID: 37612393 Review.
-
Burden of Hyperlipidemia, Cardiovascular Mortality, and COVID-19: A Retrospective-Cohort Analysis of US Data.J Am Heart Assoc. 2025 Mar 4;14(5):e037381. doi: 10.1161/JAHA.124.037381. Epub 2025 Feb 27. J Am Heart Assoc. 2025. PMID: 39526321 Free PMC article.
-
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects.Biomolecules. 2025 Mar 22;15(4):468. doi: 10.3390/biom15040468. Biomolecules. 2025. PMID: 40305153 Free PMC article. Review.
-
The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.Metabolites. 2021 Nov 28;11(12):807. doi: 10.3390/metabo11120807. Metabolites. 2021. PMID: 34940565 Free PMC article. Review.
-
Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans.Fed Pract. 2021 Nov;38(Suppl 4):e67-e71. doi: 10.12788/fp.0176. Fed Pract. 2021. PMID: 35136343 Free PMC article.
References
-
- National Heart, Lung, and Blood Institute. What is coronary heart disease? Updated October 23, 2015. www.nhlbi.nih.gov/health/health-topics/topics/cad. Accessed January 25, 2016.
-
- National Heart, Lung, and Blood Institute. What are coronary heart disease risk factors? Updated June 9, 2015. www.nhlbi.nih.gov/health/health-topics/topics/hd. Accessed August 11, 2015.
-
- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383–1389. - PubMed
-
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7–22. - PubMed
-
- Baigent C, Keech A, Kearney PM, et al; for the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267–1278. Errata in: Lancet. 2005; 366: 1358,; Lancet. 2008; 371: 2084.
LinkOut - more resources
Full Text Sources
Miscellaneous